Do analysts rate HELP or BYSI?

Cybin presently has a consensus price target of $51.75, indicating a potential upside of 724.04%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cybin is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HELP or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% BeyondSpring N/A N/A -14.00%

Do analysts prefer ACIU or BYSI?

AC Immune currently has a consensus target price of $7.50, suggesting a potential upside of 215.13%. Given AC Immune's stronger consensus rating and higher probable upside, equities analysts clearly believe AC Immune is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACIU or BYSI more profitable?

BeyondSpring has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. BeyondSpring's return on equity of 0.00% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% BeyondSpring N/A N/A -14.00%

Do analysts recommend BYSI or GALT?

Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 154.04%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galectin Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BYSI or GALT more profitable?

Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Galectin Therapeutics N/A N/A -164.69%

Do analysts recommend BYSI or FBRX?

Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 214.26%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is BYSI or FBRX more profitable?

BeyondSpring's return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Forte Biosciences N/A -106.17% -85.50%

Do analysts rate FULC or BYSI?

Fulcrum Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 125.27%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Fulcrum Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 4 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FULC or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -27.80% -26.32% BeyondSpring N/A N/A -14.00%

BeyondSpring (BYSI) Competitors

$1.85 +0.10 (+5.71%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$1.85 0.00 (0.00%)

As of 07/1/2026 05:57 PM Eastern

Compare

BYSI vs. HELP, ACIU, GALT, FBRX, and FULC

Should you buy BeyondSpring stock or one of its competitors? MarketBeat compares BeyondSpring with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeyondSpring include Cybin (HELP), AC Immune (ACIU), Galectin Therapeutics (GALT), Forte Biosciences (FBRX), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry.

How does BeyondSpring compare to Cybin?

Cybin (NASDAQ:HELP) and BeyondSpring (NASDAQ:BYSI) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

17.9% of Cybin shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
BeyondSpring	N/A	N/A	-14.00%

Cybin presently has a consensus price target of $51.75, indicating a potential upside of 724.04%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cybin is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring has higher revenue and earnings than Cybin. BeyondSpring is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
BeyondSpring	$1.75M	43.47	-$1.01M	-$0.14	N/A

In the previous week, Cybin had 8 more articles in the media than BeyondSpring. MarketBeat recorded 9 mentions for Cybin and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Cybin's score of 0.19 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Cybin	Neutral
BeyondSpring	Very Positive

Cybin has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Summary

BeyondSpring beats Cybin on 8 of the 14 factors compared between the two stocks.

How does BeyondSpring compare to AC Immune?

AC Immune (NASDAQ:ACIU) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

BeyondSpring has lower revenue, but higher earnings than AC Immune. BeyondSpring is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	56.20	-$85.03M	-$0.82	N/A
BeyondSpring	$1.75M	43.47	-$1.01M	-$0.14	N/A

BeyondSpring has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. BeyondSpring's return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
BeyondSpring	N/A	N/A	-14.00%

AC Immune has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

AC Immune currently has a consensus target price of $7.50, suggesting a potential upside of 215.13%. Given AC Immune's stronger consensus rating and higher probable upside, equities analysts clearly believe AC Immune is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, AC Immune had 3 more articles in the media than BeyondSpring. MarketBeat recorded 4 mentions for AC Immune and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat AC Immune's score of 1.30 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
AC Immune	Positive
BeyondSpring	Very Positive

Summary

AC Immune beats BeyondSpring on 9 of the 16 factors compared between the two stocks.

How does BeyondSpring compare to Galectin Therapeutics?

BeyondSpring (NASDAQ:BYSI) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

BeyondSpring has higher revenue and earnings than Galectin Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	43.47	-$1.01M	-$0.14	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Galectin Therapeutics	N/A	N/A	-164.69%

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 154.04%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Galectin Therapeutics had 7 more articles in the media than BeyondSpring. MarketBeat recorded 8 mentions for Galectin Therapeutics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Galectin Therapeutics' score of -0.09 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Very Positive
Galectin Therapeutics	Neutral

BeyondSpring has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Summary

BeyondSpring beats Galectin Therapeutics on 7 of the 13 factors compared between the two stocks.

How does BeyondSpring compare to Forte Biosciences?

BeyondSpring (NASDAQ:BYSI) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 214.26%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

BeyondSpring has higher revenue and earnings than Forte Biosciences. BeyondSpring is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	43.47	-$1.01M	-$0.14	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

BeyondSpring has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, indicating that its share price is 185% more volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Forte Biosciences	N/A	-106.17%	-85.50%

In the previous week, BeyondSpring and BeyondSpring both had 1 articles in the media. BeyondSpring's average media sentiment score of 1.87 equaled Forte Biosciences'average media sentiment score.

Company	Overall Sentiment
BeyondSpring	Very Positive
Forte Biosciences	Very Positive

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

BeyondSpring and Forte Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does BeyondSpring compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Fulcrum Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BeyondSpring's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
BeyondSpring	N/A	N/A	-14.00%

In the previous week, Fulcrum Therapeutics had 3 more articles in the media than BeyondSpring. MarketBeat recorded 4 mentions for Fulcrum Therapeutics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Fulcrum Therapeutics' score of 0.61 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulcrum Therapeutics	Positive
BeyondSpring	Very Positive

Fulcrum Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 125.27%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Fulcrum Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring has lower revenue, but higher earnings than Fulcrum Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.03	-$74.88M	-$1.15	N/A
BeyondSpring	$1.75M	43.47	-$1.01M	-$0.14	N/A

Summary

Fulcrum Therapeutics beats BeyondSpring on 8 of the 15 factors compared between the two stocks.

Get BeyondSpring News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BYSI vs. The Competition

Export

Metric	BeyondSpring	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$71.96M	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.15%
P/E Ratio	-13.21	21.28	27.67	25.27
Price / Sales	43.47	324.37	533.25	101.18
Price / Cash	15.40	141.54	47.99	59.26
Price / Book	-3.14	8.71	10.96	6.62
Net Income	-$1.01M	$23.87M	$3.57B	$336.83M
7 Day Performance	15.63%	4.34%	2.88%	3.19%
1 Month Performance	8.82%	6.62%	3.69%	0.86%
1 Year Performance	-19.21%	61.64%	34.39%	27.51%

BeyondSpring Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BYSI BeyondSpring	0.263 of 5 stars	$1.85 +5.7%	N/A	-23.6%	$71.96M	$1.75M	N/A	80	Positive News High Trading Volume
HELP Cybin	2.8855 of 5 stars	$5.09 +4.9%	$58.75 +1,054.2%	N/A	$262.80M	N/A	N/A	50	Earnings Report Analyst Forecast High Trading Volume
ACIU AC Immune	3.1892 of 5 stars	$2.54 +3.7%	$7.50 +195.3%	+20.2%	$258.50M	$4.31M	N/A	140	News Coverage Positive News Analyst Forecast
GALT Galectin Therapeutics	1.6469 of 5 stars	$3.92 +25.6%	$11.00 +180.6%	+95.0%	$258.16M	N/A	N/A	9	News Coverage Insider Trade High Trading Volume
FBRX Forte Biosciences	1.7523 of 5 stars	$18.54 +2.1%	$67.00 +261.4%	+71.4%	$257.52M	N/A	N/A	5	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BYSI) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeyondSpring (BYSI) Competitors

BYSI vs. HELP, ACIU, GALT, FBRX, and FULC

How does BeyondSpring compare to Cybin?

Summary

How does BeyondSpring compare to AC Immune?

Summary

How does BeyondSpring compare to Galectin Therapeutics?

Summary

How does BeyondSpring compare to Forte Biosciences?

Summary

How does BeyondSpring compare to Fulcrum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeyondSpring (BYSI) Competitors

BYSI vs. HELP, ACIU, GALT, FBRX, and FULC

How does BeyondSpring compare to Cybin?

Do institutionals & insiders believe in HELP or BYSI?

Is HELP or BYSI more profitable?

Do analysts rate HELP or BYSI?

Which has higher valuation & earnings, HELP or BYSI?

Does the media refer more to HELP or BYSI?

Which has more risk & volatility, HELP or BYSI?

Summary

How does BeyondSpring compare to AC Immune?

Which has higher earnings and valuation, ACIU or BYSI?

Is ACIU or BYSI more profitable?

Which has more risk & volatility, ACIU or BYSI?

Do analysts prefer ACIU or BYSI?

Do institutionals & insiders hold more shares of ACIU or BYSI?

Does the media refer more to ACIU or BYSI?

Summary

How does BeyondSpring compare to Galectin Therapeutics?

Which has higher valuation and earnings, BYSI or GALT?

Is BYSI or GALT more profitable?

Do insiders & institutionals have more ownership in BYSI or GALT?

Do analysts recommend BYSI or GALT?

Does the media favor BYSI or GALT?

Which has more volatility and risk, BYSI or GALT?

Summary

How does BeyondSpring compare to Forte Biosciences?

Do analysts recommend BYSI or FBRX?

Which has better valuation & earnings, BYSI or FBRX?

Which has more volatility & risk, BYSI or FBRX?

Is BYSI or FBRX more profitable?

Does the media favor BYSI or FBRX?

Do institutionals & insiders have more ownership in BYSI or FBRX?

Summary

How does BeyondSpring compare to Fulcrum Therapeutics?

Which has more risk and volatility, FULC or BYSI?

Do insiders and institutionals have more ownership in FULC or BYSI?

Is FULC or BYSI more profitable?

Does the media prefer FULC or BYSI?

Do analysts rate FULC or BYSI?

Which has stronger earnings and valuation, FULC or BYSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools